HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DHEA Debate Returns To Fore: Anabolic Steroid Status Sought In Grassley Bill

This article was originally published in The Tan Sheet

Executive Summary

A new bill sponsored by Sen. Charles Grassley (R-Iowa) would regulate dehydroepiandrosterone (DHEA) as an anabolic steroid under the Controlled Substances Act

You may also be interested in...



Grassley’s Swing At Illegal Anabolic Steroid Use Unfairly Strikes DHEA – CRN

Legislation introduced in response to a report on steroid use in Major League Baseball that would put an age restriction on sales of performance-enhancing drugs and supplements - including DHEA - is a "misdirected attempt ... based on emotional rhetoric" to curb illegal anabolic steroid use, industry leaders say

DHEA bill returns

Sen. Chuck Grassley, R-Iowa, on March 5 reintroduces a bill to list dehydroepiandrosterone as an anabolic steroid under the Controlled Substances Act. Co-sponsored by Sens. Dick Durbin, D-Ill. and John McCain, R-Ariz., S. 762 has been referred to the Judiciary Committee. In a same day release, Grassley says DHEA has "a number of potential long-term physical and psychological effects" including heart disease, cancer, stroke and liver damage. Industry groups maintain DHEA has little to no potential for abuse. Grassley previously introduced the measure in 2005 (1"The Tan Sheet" June 6, 2005, p. 11)...

Trade Groups Make AER Legislation Wish List; Preemption Is Top Priority

Federal legislation requiring mandatory adverse event reporting for dietary supplements is both "likely" and "good" but must include preemption of state laws, trade groups asserted during a "State of the Industry" seminar Nov. 11 at SupplySide West in Las Vegas

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS127095

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel